Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120

1.

Retraction notice to "A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells".

Mehta PP, Kung PP, Yamazaki S, Walls M, Shen A, Nguyen L, Gehring MR, Los G, Smeal T, Yin MJ.

Cancer Lett. 2018 May 28;422:132. doi: 10.1016/j.canlet.2018.03.019. No abstract available.

PMID:
29579439
2.

Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules.

Murray J, Thomas H, Berry P, Kyle S, Patterson M, Jones C, Los G, Hostomsky Z, Plummer ER, Boddy AV, Curtin NJ.

Br J Cancer. 2014 Apr 15;110(8):1977-84. doi: 10.1038/bjc.2014.91. Epub 2014 Feb 20.

3.

Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation.

Fang DD, Zhang CC, Gu Y, Jani JP, Cao J, Tsaparikos K, Yuan J, Thiel M, Jackson-Fisher A, Zong Q, Lappin PB, Hayashi T, Schwab RB, Wong A, John-Baptiste A, Bagrodia S, Los G, Bender S, Christensen J, Vanarsdale T.

PLoS One. 2013 Jun 27;8(6):e67258. doi: 10.1371/journal.pone.0067258. Print 2013.

4.

Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a non-small cell lung cancer cell line.

Fang DD, Cao J, Jani JP, Tsaparikos K, Blasina A, Kornmann J, Lira ME, Wang J, Jirout Z, Bingham J, Zhu Z, Gu Y, Los G, Hostomsky Z, Vanarsdale T.

Front Med. 2013 Dec;7(4):462-76. doi: 10.1007/s11684-013-0270-6. Epub 2013 Jul 2.

PMID:
23820871
5.

Targeting fibroblast growth factors in cancer: the key is what not to block.

Baker KP, Los G.

Oncotarget. 2013 Jul;4(7):952-3. No abstract available.

6.

Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer.

Ihnen M, zu Eulenburg C, Kolarova T, Qi JW, Manivong K, Chalukya M, Dering J, Anderson L, Ginther C, Meuter A, Winterhoff B, Jones S, Velculescu VE, Venkatesan N, Rong HM, Dandekar S, Udar N, Jänicke F, Los G, Slamon DJ, Konecny GE.

Mol Cancer Ther. 2013 Jun;12(6):1002-15. doi: 10.1158/1535-7163.MCT-12-0813. Epub 2013 May 31.

7.

A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo.

Kuruma H, Matsumoto H, Shiota M, Bishop J, Lamoureux F, Thomas C, Briere D, Los G, Gleave M, Fanjul A, Zoubeidi A.

Mol Cancer Ther. 2013 May;12(5):567-76. doi: 10.1158/1535-7163.MCT-12-0798. Epub 2013 Mar 14.

8.

Development of a dehalogenase-based protein fusion tag capable of rapid, selective and covalent attachment to customizable ligands.

Encell LP, Friedman Ohana R, Zimmerman K, Otto P, Vidugiris G, Wood MG, Los GV, McDougall MG, Zimprich C, Karassina N, Learish RD, Hurst R, Hartnett J, Wheeler S, Stecha P, English J, Zhao K, Mendez J, Benink HA, Murphy N, Daniels DL, Slater MR, Urh M, Darzins A, Klaubert DH, Bulleit RF, Wood KV.

Curr Chem Genomics. 2012;6:55-71. doi: 10.2174/1875397301206010055. Epub 2012 Oct 5.

9.

Match criteria for human cell line authentication: where do we draw the line?

Capes-Davis A, Reid YA, Kline MC, Storts DR, Strauss E, Dirks WG, Drexler HG, MacLeod RA, Sykes G, Kohara A, Nakamura Y, Elmore E, Nims RW, Alston-Roberts C, Barallon R, Los GV, Nardone RM, Price PJ, Steuer A, Thomson J, Masters JR, Kerrigan L.

Int J Cancer. 2013 Jun 1;132(11):2510-9. doi: 10.1002/ijc.27931. Epub 2012 Nov 28.

10.

Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621.

Michaud NR, Jani JP, Hillerman S, Tsaparikos KE, Barbacci-Tobin EG, Knauth E, Putz H Jr, Campbell M, Karam GA, Chrunyk B, Gebhard DF, Green LL, Xu JJ, Dunn MC, Coskran TM, Lapointe JM, Cohen BD, Coleman KG, Bedian V, Vincent P, Kajiji S, Steyn SJ, Borzillo GV, Los G.

MAbs. 2012 Nov-Dec;4(6):710-23. doi: 10.4161/mabs.22160. Epub 2012 Sep 24.

11.

Dose-dependent effects of small-molecule antagonists on the genomic landscape of androgen receptor binding.

Zhu Z, Shi M, Hu W, Estrella H, Engebretsen J, Nichols T, Briere D, Hosea N, Los G, Rejto PA, Fanjul A.

BMC Genomics. 2012 Jul 31;13:355. doi: 10.1186/1471-2164-13-355.

12.

Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitor.

Zou HY, Li Q, Lee JH, Arango ME, Burgess K, Qiu M, Engstrom LD, Yamazaki S, Parker M, Timofeevski S, Cui JJ, McTigue M, Los G, Bender SL, Smeal T, Christensen JG.

Mol Cancer Ther. 2012 Apr;11(4):1036-47. doi: 10.1158/1535-7163.MCT-11-0839. Epub 2012 Mar 2.

13.

Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.

Guo C, Linton A, Kephart S, Ornelas M, Pairish M, Gonzalez J, Greasley S, Nagata A, Burke BJ, Edwards M, Hosea N, Kang P, Hu W, Engebretsen J, Briere D, Shi M, Gukasyan H, Richardson P, Dack K, Underwood T, Johnson P, Morell A, Felstead R, Kuruma H, Matsimoto H, Zoubeidi A, Gleave M, Los G, Fanjul AN.

J Med Chem. 2011 Nov 10;54(21):7693-704. doi: 10.1021/jm201059s. Epub 2011 Oct 7.

PMID:
21936524
14.

Chromophore-assisted light inactivation of HaloTag fusion proteins labeled with eosin in living cells.

Takemoto K, Matsuda T, McDougall M, Klaubert DH, Hasegawa A, Los GV, Wood KV, Miyawaki A, Nagai T.

ACS Chem Biol. 2011 May 20;6(5):401-6. doi: 10.1021/cb100431e. Epub 2011 Jan 20.

PMID:
21226520
15.

Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.

Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S, Mukhopadhyay A, Los G, Hostomsky Z, Plummer ER, Edmondson RJ, Curtin NJ.

J Natl Cancer Inst. 2011 Feb 16;103(4):334-46. doi: 10.1093/jnci/djq509. Epub 2010 Dec 23.

PMID:
21183737
16.

RETRACTED: A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells.

Mehta PP, Kung PP, Yamazaki S, Walls M, Shen A, Nguyen L, Gehring MR, Los G, Smeal T, Yin MJ.

Cancer Lett. 2011 Jan 1;300(1):30-9. doi: 10.1016/j.canlet.2010.09.002. Retraction in: Cancer Lett. 2018 May 28;422:132.

PMID:
20926183
17.

P-cadherin expression as a prognostic biomarker in a 3992 case tissue microarray series of breast cancer.

Turashvili G, McKinney SE, Goktepe O, Leung SC, Huntsman DG, Gelmon KA, Los G, Rejto PA, Aparicio SA.

Mod Pathol. 2011 Jan;24(1):64-81. doi: 10.1038/modpathol.2010.189. Epub 2010 Sep 17.

18.

PF-03732010: a fully human monoclonal antibody against P-cadherin with antitumor and antimetastatic activity.

Zhang CC, Yan Z, Zhang Q, Kuszpit K, Zasadny K, Qiu M, Painter CL, Wong A, Kraynov E, Arango ME, Mehta PP, Popoff I, Casperson GF, Los G, Bender S, Anderes K, Christensen JG, VanArsdale T.

Clin Cancer Res. 2010 Nov 1;16(21):5177-88. doi: 10.1158/1078-0432.CCR-10-1343. Epub 2010 Sep 9.

19.

Recommendation of short tandem repeat profiling for authenticating human cell lines, stem cells, and tissues.

Barallon R, Bauer SR, Butler J, Capes-Davis A, Dirks WG, Elmore E, Furtado M, Kline MC, Kohara A, Los GV, MacLeod RA, Masters JR, Nardone M, Nardone RM, Nims RW, Price PJ, Reid YA, Shewale J, Sykes G, Steuer AF, Storts DR, Thomson J, Taraporewala Z, Alston-Roberts C, Kerrigan L.

In Vitro Cell Dev Biol Anim. 2010 Oct;46(9):727-32. doi: 10.1007/s11626-010-9333-z. Epub 2010 Jul 8.

20.

Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors.

Mukhopadhyay A, Elattar A, Cerbinskaite A, Wilkinson SJ, Drew Y, Kyle S, Los G, Hostomsky Z, Edmondson RJ, Curtin NJ.

Clin Cancer Res. 2010 Apr 15;16(8):2344-51. doi: 10.1158/1078-0432.CCR-09-2758. Epub 2010 Apr 6.

21.

PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy.

Jani JP, Arcari J, Bernardo V, Bhattacharya SK, Briere D, Cohen BD, Coleman K, Christensen JG, Emerson EO, Jakowski A, Hook K, Los G, Moyer JD, Pruimboom-Brees I, Pustilnik L, Rossi AM, Steyn SJ, Su C, Tsaparikos K, Wishka D, Yoon K, Jakubczak JL.

Mol Cancer Ther. 2010 Apr;9(4):883-94. doi: 10.1158/1535-7163.MCT-09-0915. Epub 2010 Mar 30.

22.

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.

Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, Los G, Slamon DJ.

Breast Cancer Res. 2009;11(5):R77. doi: 10.1186/bcr2419.

23.

Direct pH measurements by using subcellular targeting of 5(and 6-) carboxyseminaphthorhodafluor in mammalian cells.

Benink H, McDougall M, Klaubert D, Los G.

Biotechniques. 2009 Sep;47(3):769-74. doi: 10.2144/000113220.

24.

Fluorogenic affinity label for the facile, rapid imaging of proteins in live cells.

Watkins RW, Lavis LD, Kung VM, Los GV, Raines RT.

Org Biomol Chem. 2009 Oct 7;7(19):3969-75. doi: 10.1039/b907664f. Epub 2009 Jul 31. Erratum in: Org Biomol Chem. 2009 Dec 21;7(24):5276.

25.

Structure-based design of novel human Pin1 inhibitors (I).

Guo C, Hou X, Dong L, Dagostino E, Greasley S, Ferre R, Marakovits J, Johnson MC, Matthews D, Mroczkowski B, Parge H, Vanarsdale T, Popoff I, Piraino J, Margosiak S, Thomson J, Los G, Murray BW.

Bioorg Med Chem Lett. 2009 Oct 1;19(19):5613-6. doi: 10.1016/j.bmcl.2009.08.034. Epub 2009 Aug 13.

PMID:
19729306
26.

Peroxisome dynamics in cultured mammalian cells.

Huybrechts SJ, Van Veldhoven PP, Brees C, Mannaerts GP, Los GV, Fransen M.

Traffic. 2009 Nov;10(11):1722-33. doi: 10.1111/j.1600-0854.2009.00970.x. Epub 2009 Aug 4.

27.

In vivo stable tumor-specific painting in various colors using dehalogenase-based protein-tag fluorescent ligands.

Kosaka N, Ogawa M, Choyke PL, Karassina N, Corona C, McDougall M, Lynch DT, Hoyt CC, Levenson RM, Los GV, Kobayashi H.

Bioconjug Chem. 2009 Jul;20(7):1367-74. doi: 10.1021/bc9001344.

28.

In vivo labeling method using a genetic construct for nanoscale resolution microscopy.

Schröder J, Benink H, Dyba M, Los GV.

Biophys J. 2009 Jan;96(1):L01-3. doi: 10.1016/j.bpj.2008.09.032.

29.

HaloTag: a novel protein labeling technology for cell imaging and protein analysis.

Los GV, Encell LP, McDougall MG, Hartzell DD, Karassina N, Zimprich C, Wood MG, Learish R, Ohana RF, Urh M, Simpson D, Mendez J, Zimmerman K, Otto P, Vidugiris G, Zhu J, Darzins A, Klaubert DH, Bulleit RF, Wood KV.

ACS Chem Biol. 2008 Jun 20;3(6):373-82. doi: 10.1021/cb800025k.

PMID:
18533659
30.

Pharmacologic properties of AG-012986, a pan-cyclin-dependent kinase inhibitor with antitumor efficacy.

Zhang C, Lundgren K, Yan Z, Arango ME, Price S, Huber A, Higgins J, Troche G, Skaptason J, Koudriakova T, Nonomiya J, Yang M, O'Connor P, Bender S, Los G, Lewis C, Jessen B.

Mol Cancer Ther. 2008 Apr;7(4):818-28. doi: 10.1158/1535-7163.MCT-07-0440.

31.

Spatial separation and bidirectional trafficking of proteins using a multi-functional reporter.

Svendsen S, Zimprich C, McDougall MG, Klaubert DH, Los GV.

BMC Cell Biol. 2008 Apr 2;9:17. doi: 10.1186/1471-2121-9-17.

32.

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.

Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, Yamazaki S, Alton GR, Mroczkowski B, Los G.

Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3314-22.

33.

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.

Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, Koudriakova TB, Alton G, Cui JJ, Kung PP, Nambu MD, Los G, Bender SL, Mroczkowski B, Christensen JG.

Cancer Res. 2007 May 1;67(9):4408-17.

34.

XAF1 mediates tumor necrosis factor-alpha-induced apoptosis and X-linked inhibitor of apoptosis cleavage by acting through the mitochondrial pathway.

Straszewski-Chavez SL, Visintin IP, Karassina N, Los G, Liston P, Halaban R, Fadiel A, Mor G.

J Biol Chem. 2007 Apr 27;282(17):13059-72. Epub 2007 Feb 28.

35.

The HaloTag: a novel technology for cell imaging and protein analysis.

Los GV, Wood K.

Methods Mol Biol. 2007;356:195-208.

PMID:
16988404
36.

Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL.

Bauer JA, Trask DK, Kumar B, Los G, Castro J, Lee JS, Chen J, Wang S, Bradford CR, Carey TE.

Mol Cancer Ther. 2005 Jul;4(7):1096-104.

37.

Gene expression profiling to characterize anticancer drug sensitivity.

Breaux JK, Los G.

Methods Mol Med. 2005;111:197-231.

PMID:
15911981
38.

cDNA microarray-based identification of genes and pathways associated with oxaliplatin resistance.

Samimi G, Manorek G, Castel R, Breaux JK, Cheng TC, Berry CC, Los G, Howell SB.

Cancer Chemother Pharmacol. 2005 Jan;55(1):1-11. Epub 2004 Sep 16.

PMID:
15378272
39.

Diazonamide A and a synthetic structural analog: disruptive effects on mitosis and cellular microtubules and analysis of their interactions with tubulin.

Cruz-Monserrate Z, Vervoort HC, Bai R, Newman DJ, Howell SB, Los G, Mullaney JT, Williams MD, Pettit GR, Fenical W, Hamel E.

Mol Pharmacol. 2003 Jun;63(6):1273-80.

PMID:
12761336
40.

Identification of transdominant-negative genetic suppressor elements derived from hMSH2 that mediate resistance to 6-thioguanine.

de las Alas MM, Los G, Lin X, Kurdi-Haidar B, Manorek G, Howell SB.

Mol Pharmacol. 2002 Nov;62(5):1198-206.

PMID:
12391284
41.

Using mRNA expression profiling to determine anticancer drug efficacy.

Los G, Yang F, Samimi G, Manorek G, Guerorguieva IM, Howell S, van Erp N, Breaux JK.

Cytometry. 2002 Jan 1;47(1):66-71.

PMID:
11774355
42.

Identification of gene clusters differentially expressed during the cellular injury responses (CIR) to cisplatin.

Johnsson A, Byrne P, de Bruin R, Weiner D, Wong J, Los G.

Br J Cancer. 2001 Oct 19;85(8):1206-10.

43.

Nicotine affects the signaling of the death pathway, reducing the response of head and neck cancer cell lines to DNA damaging agents.

Onoda N, Nehmi A, Weiner D, Mujumdar S, Christen R, Los G.

Head Neck. 2001 Oct;23(10):860-70.

PMID:
11592233
44.

Noninvasive, in-situ measurement of drug concentrations in tissue using optical spectroscopy.

Bigio IJ, Mourant JR, Los G.

J Gravit Physiol. 1999 Jul;6(1):P173-5.

PMID:
11543008
45.

Recombinant derivatives of clostridial neurotoxins as delivery vehicles for proteins and small organic molecules.

Zdanovskaia MV, Los G, Zdanovsky AG.

J Protein Chem. 2000 Nov;19(8):699-707.

PMID:
11307955
46.
47.

Identification of genes differentially expressed in association with acquired cisplatin resistance.

Johnsson A, Zeelenberg I, Min Y, Hilinski J, Berry C, Howell SB, Los G.

Br J Cancer. 2000 Oct;83(8):1047-54.

48.

Increase in tumor GADD153 mRNA level following treatment correlates with response to paclitaxel.

de las Alas MM, Christen RD, Gately DP, Weiner DE, Benbatoul K, Kirmani S, D'Agostino HR, Plaxe SC, Darrah D, McClay EF, Aebi S, Howell SB, Los G.

Cancer Chemother Pharmacol. 2000;45(5):381-8.

PMID:
10803921
49.

A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel.

Aebi S, Schnider TW, Los G, Heath DD, Darrah D, Kirmani S, McClay EF, D'Agostino H, Plaxe SC, Fink D, De las Alas MM, Howell SB, Christen RD.

Cancer Chemother Pharmacol. 1999;44(3):259-65.

PMID:
10453729
50.

Quantitation of the change in GADD153 messenger RNA level as a molecular marker of tumor response in head and neck cancer.

Los G, Benbatoul K, Gately DP, Barton R, Christen R, Robbins KT, Vicario D, Kirmani S, Orloff LA, Weisman R, Howell SB.

Clin Cancer Res. 1999 Jul;5(7):1610-8.

Supplemental Content

Support Center